A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

Neuroendocrine Tumors

(2017) Matthew H. Kulke et al.   Journal of the National Comprehensive Cancer Network

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors

(2012) Diane L. Reidy-Lagunes et al.   CANCER

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

(2011) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

(2011) C Garofalo et al.   ONCOGENE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

The Pathologic Classification of Neuroendocrine Tumors

(2010) David S. Klimstra et al.   PANCREAS

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

(2009) P. J. Beltran et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

(2008) P. Haluska et al.   MOLECULAR CANCER THERAPEUTICS